Drug Profile
Research programme: purinoceptor P2U agonists - EPIX
Alternative Names: EPX-16006; MDT-006Latest Information Update: 04 Nov 2017
Price :
$50
*
At a glance
- Originator EPIX Pharmaceuticals
- Developer Cystic Fibrosis Foundation Therapeutics; EPIX Pharmaceuticals; MicroDose Therapeutx
- Class Small molecules
- Mechanism of Action Purinoceptor P2U agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Constipation; Irritable bowel syndrome
- Discontinued Cystic fibrosis
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for preclinical development in Constipation in USA (PO)
- 04 Nov 2017 No recent reports of development identified for preclinical development in Irritable-bowel-syndrome in USA (PO)
- 08 Jul 2013 MicroDose Therapeutx has been acquired by Teva Pharmaceutical Industries